Skip to main content

Cancer Genomics Research

Cancer Genomics Research


The Importance of Cancer Genomics Research

The study of cancer genomes (all the DNA in cancer cells) has revealed the mind-boggling complexity of genomic changes that drive cancer growth and survival. This knowledge has greatly expanded our understanding of how cancer develops and progresses. Ultimately, it has led to new ways of diagnosing and treating cancer, as well as new ways of identifying those at high risk of developing cancer. In short, genomics research has changed the way we see cancer.

Large-scale research projects such as The Cancer Genome Atlas (TCGA), and its pediatric counterpart Therapeutically Applicable Research to Generate Effective Treatments (TARGET), have surveyed and cataloged the genomic changes in multiple types of cancer. The discovery of novel cancer-associated genetic changes has led to an explosion of therapies that target specific changes and tests that identify patients whose cancers harbor those changes—an approach to cancer treatment known as precision medicine.

Genomics studies have also revealed unexpected genetic similarities across different types of tumors, shifting the way we define cancer. Treatments are typically given based on the tumor’s location in the body, such as the brain or lung. But a handful of new cancer drugs are used to treat tumors with specific genetic or molecular features, no matter where in the body the cancer started growing.

On the other hand, genomics research has also shown how different cancers can be, even when they started growing in the same organ. This finding has helped explain why some subtypes of tumors grow at different rates and why cancer treatments don’t work the same way in every patient.

NCI plays a key role in large-scale genomics research by facilitating collaborations between scientists of different disciplines, providing funding, and providing access to state-of-the-art technologies, data sets, and other resources.

In addition to genomics, cancer researchers are also creating large-scale catalogs of other kinds of molecular changes in cancer, including epigenomic, transcriptomic, proteomic, and metabolomic changes. These studies have further expanded our understanding of cancer and have led to new ideas for treating it.

The results of these projects illustrate the wide-ranging variation of genetic and molecular changes in cancer, and provide a better understanding of what causes cancer at the molecular level.



Selected NCI Activities in Cancer Genomics Research

Exploring the genetic and molecular foundations of cancer is a vital part of NCI’s research efforts. The following list highlights NCI-led or NCI-funded activities related to genomics and other “omics” research.

Building Genomics Data Sets

Large-scale research projects use omics technologies to catalog the molecular changes in multiple types of cancer.The Human Tumor Atlas Network is constructing 3-dimensional atlases of human cancers as they change over time, including single-cell analyses of genomics, epigenomics, and transcriptomics. The network is generating adult and pediatric atlases and strives to include minority and underserved patients across cancer types and stages of disease.

The Clinical Proteomic Tumor Analysis Consortium is using large-scale proteomic and genomic analyses, or proteogenomics, to characterize multiple types of cancer. The consortium is also using proteogenomics to answer questions about toxicity and resistance in clinical trials of new cancer drugs.
NCI leads several projects to molecularly characterize large collections of cancers as well as collecting a rich profile of clinical features and outcomes. The Genomic Data Analysis Network develops cutting-edge computational tools and performs an initial analysis of the data from these projects, providing a launching pad for a broad community of researchers.

The Participant Engagement and Cancer Genome Sequencing (PE-CGS) Research Network Exit Disclaimer, a Cancer Moonshot initiative, is using direct participant engagement approaches to promote cancer genome sequencing programs for rare cancers, highly lethal cancers, cancers that occur at an early age, cancers that disproportionately affect certain populations, and cancers that are prevalent in understudied populations.
 
The Childhood Cancer Data Initiative (CCDI) is gathering clinical care and research data—including genomics data—from children, teens, and young adults with cancer. CCDI has also created infrastructure to share this data with researchers to help them learn faster and on a larger scale than is possible for any single institution.

Connecting Genomics Data to Cancer Biology

NCI conducts and supports research to find out how genetic and other molecular changes in cancer cells affect cancer development, cancer progression, and treatment response.


The Cancer Target Discovery and Development Program is a network of research centers devoted to studying how molecular changes found in cancers affect cancer cells and explore opportunities to target those changes with new therapies.

The Epidemiology and Genomics Research Program supports research in human populations to understand genomic determinants of cancer occurrence and cancer outcomes, and translate findings to clinical and public health interventions.

NCI researchers use molecular and genomic profiling to study the causes of cancer. This enables a better understanding of how normal cells transform into cancer cells, and to pinpoint internal processes and external exposures associated with specific molecular or genomic subtypes of cancer.

The Cancer Systems Biology Consortium integrates and analyzes large omics data sets to get a birds-eye view of the molecular changes in cancer, how these changes interact with one another, and how they change over time and space.

Using Genomics in Clinical Trials

NCI clinical trials are among the first to use genomic testing to match patients to cancer treatments based on the genetic changes in their tumors.ComboMATCH is a group of clinical trials that are using genetic testing to find genetic changes in patients’ cancers and potentially match them to combinations of cancer treatments that target those genetic changes.

ALCHEMIST is a set of precision medicine lung cancer trials designed to evaluate whether adding targeted therapy based on patients' tumor genetics can help prevent lung cancer from returning after surgery.

NCI-COG Pediatric MATCH is an international cancer treatment clinical trial for children, teens, and young adults that is testing the use of precision medicine for childhood cancers.

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more